Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Multiple myeloma (MM) is a plasma cell malignancy with limited curative options.
• RAS/RAF gene mutations are frequent in MM, suggesting RAS/RAF/MEK/ERK signaling as a therapeutic target.
• Clinical responses to MEK inhibitors in RAS-mutant MM are inconsistent, necessitating further investigation.

Purpose of the Study:

• To investigate the association between RAS/RAF mutation status, MEK/ERK pathway activation, and clinical outcomes in newly diagnosed and relapsed/refractory multiple myeloma.
• To determine if specific RAS/RAF mutations correlate with downstream pathway activation.
• To inform more precise therapeutic strategies for multiple myeloma.

Main Methods:

• Analysis of 180 tissue biopsies from 103 patients with newly diagnosed MM (NDMM) and 77 patients with relapsed/refractory MM (rrMM).
• Assessment of RAS/RAF mutation status using targeted sequencing.
• Evaluation of MEK/ERK pathway activation via phospho-ERK immunohistochemistry.

Main Results:

• RAS/BRAF mutations were significantly enriched in rrMM compared to NDMM (P=0.011), primarily due to increased NRAS mutations (P=0.010).
• BRAF mutations correlated with downstream signaling activation.
• Only KRAS (P=0.030) and specifically KRAS^G12D and BRAF^V600E mutations were consistently associated with ERK activation (P<0.001 and P=0.006, respectively).

Conclusions:

• A more specific stratification strategy is needed for targeted therapies in MM.
• Combining assessment of protein-level pathway activation with detailed RAS/RAF mutation status is crucial.
• This approach can lead to more precise and effective application of targeted therapies, such as BRAF/MEK inhibitors in MM.